Investigation Launched into Potential Securities Fraud of Prestige Consumer Healthcare, Inc. Amid Stock Drop
Investigation Launched into Prestige Consumer Healthcare, Inc.
In the wake of disappointing results for the fourth quarter of fiscal year 2026, Prestige Consumer Healthcare, Inc. (NYSE: PBH) is now facing serious scrutiny over its financial disclosures and guidance. The company's shares plummeted after adjusted earnings per share (EPS) landed at $1.23, considerably lower than the expected $1.39, along with revenue dropping to $281.6 million, which also fell short of projections.
The primary concern revolves around the company's handling of its supply chain, particularly related to its Clear Eyes product. Investors were led to believe that the supply chain challenges had been resolving, as indicated by management statements in previous earnings calls. CEO Ron Lombardi had assured investors that the company was well-positioned for improvement, stating it would
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.